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Abstract
Angiogenesis, the formation of new blood vessels from pre-existing
vascular structures, is a crucial process in growing and maintaining the vascular
system. This process is controlled primarily by the VEGF family of molecules and
their receptors (VEGFRs). Poor vascularization of adipose tissue is often
associated with impairment of insulin sensitivity and metabolism; thus, the
improvement of angiogenesis holds therapeutic potential as a strategy to combat
obesity and its complications. This paper builds on research by Dr. M.R. Robciuc
et al. to explore the capabilities of the VEGFB/VEGFR1 pathway in promoting
angiogenesis. Particularly, we examined whether in vitro cultures of human
umbilical vein endothelial cells (HUVECs) can be used to confirm a previously
described interplay between VEGFB/VEGFR1 and VEGFA/VEGFR2. Furthermore,
we assessed the phenotypic effects of AAV-delivered VEGF-B, namely whether it
could increase angiogenesis in inguinal white adipose tissue in apoEKO mice.
Finally, we attempted to characterize a ubiquitous deletion of VEGFR1 (Flt-1)
with ROSA promoter Cre-Lox mice. With the understanding that the
VEGFB/VEGFR1 pathway can be a potential treatment option to combat obesity,
these experiments examine the pathway in different circumstances in vitro and
in vivo as both an exploration and assessment of translational viability.

Introduction
VEGF’s and VEGFR’s
Blood vessels grow in a stalk-like manner to vascularize tissues in a
process known as angiogenesis. Endothelial cells grow with the guidance of
filopodia towards proangiogenic signals, eventually meeting other endothelial
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cell stalks to form vessels1. These blood vessels are necessary to provide oxygen
and nutrients to tissues, making angiogenesis a crucial aspect of physiological
development and homeostasis. Pathological angiogenic activity can be a major
contributor in various forms of inflammation, cancer, and obesity/obesityrelated complications.
The Vascular Endothelial Growth Factors (VEGF’s) are secreted dimeric
glycoproteins that regulate vascular development by modulating endothelial cell
proliferation, growth, directionality, and permeability. Members of the VEGF
family relevant to mammalian physiology are VEGFA, VEGFB, VEGFC, and
VEGFD. VEGF’s interface with endothelial cells via VEGFRs, which have their own
intrinsic properties. VEGFR1(Flt-1) and VEGFR2(Flk-2) are involved in
angiogenesis, while VEGFR3 is more relevant in lymphangiogenesis. VEGFR’s are
endothelial cell transmembrane proteins characterized by an extracellular
domain consisting of seven homologous immunoglobulin (Ig) ligand binding
subunits. These subunits dimerize upon VEGF ligand binding, activating an
intercellular tyrosine-kinase domain2. This interaction produces responses
characteristic of auto-phosphorylated tyrosine kinase receptors, namely the
activation of phospholipase C/protein kinase C and PI3K/MAPK pathways,
culminating in proliferation programs and vasculature formation3. In this way,
VEGF’s and VEGFR’s drive the growth of endothelial cells to form blood vessels,
which eventually create the vasculature necessary for homeostasis and nutrient
supply.
Potente, M., Gerhardt,H. , and Carmeliet,P. (2011) “Basic and Therapeutic Aspects of
Angiogenesis.” Cell.
2 Jeltsch, Michael; Leppänen, Veli-Matti; Saharinen, Pipsa; Alitalo, Kari. (2013).Receptor Tyrosine
Kinase-Mediated Angiogenesis. Cold Spring Harbor Perspectives in Biology. a009183.
3 Koch, Sina and Claesson-Welsh, Lena. (2012)“Signal Transduction by Vascular Endothelial
Growth Factor Receptors.” Cold Spring Harbor Perspectives in Medicine.
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This signaling pathway is contextual to the specific interactions between
the VEGF’s and the VEGFR’s. VEGFA is the most important and effective
angiogenic molecule with respect to growth and vessel formation; both knockout
(VEGFA-/-) and heterozygous (VEGFA +/-) mutations are embryonically lethal
due to poor blood vessel formation4. Alternative splicing of VEGFA can produce
four isoforms, all of which possess a heparin-binding element to facilitate ligand
binding with VEGR1 and VEGFR2. VEGFA binding to VEGFR2 (Flk-2) is essential
for angiogenesis to occur and leads to strong increases in endothelial cell
proliferation, migration, and permeability5. Meanwhile, growth signaling and
response from VEGFA ligand binding to VEGFR1 (Flt-1) are far weaker and less
robust. VEGFR1 deficient mice are not viable due to a disorganized and
overgrown vasculature6, however this phenomena is reversed when only the
tyrosine kinase portion of VEGFR1 is deleted7. This, along with the discovery8 of
a soluble isoform of VEGFR1 (sVEGFR1) lacking the intercellular domain
altogether, indicates that VEGFR1 acts to regulate VEGFA concentrations by
“trapping” it in an otherwise poorly-angiogenic receptor. This regulation
prevents the endothelial cell overgrowth and over-permeability which might
otherwise occur if VEGFA binding to VEGFR2 is left unchecked. Thus, ligand
binding of VEGFA with VEGFR2 is a robust angiogenic pathway, while VEGFA
binding to VEGFR1 serves a more regulatory role.

Shibuya, Masabumi. (2012) ”Vascular endothelial growth factor and its receptor system:
physiological functions in angiogenesis and pathological roles in various diseases.”
5 Lohela et al. (2009) “VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.”
Cell Biology.
6 Fong et al. (1995) “Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of
vascular endothelium.” Nature.
7 Hiratsuka, Sachie et al. (1998) “Flt-1 lackign the tyrosine kinase domain is sufficient for normal
development and angiogenesis in mice.” Natl. Acad. Sci. USA: Developmental Biology.
8 Koch, Sina and Claesson-Welsh, Lena
4
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Recent research has uncovered a further nuance to angiogenic regulation
involving a related angiogenic molecule, VEGFB. Historically less characterized,
this ligand exists in two main isoforms, VEGFB165 and VEGF186, and has been
shown to interact with VEGFR1, VEGFR2, and NRP-1, another receptor protein
relevant to angiogenesis. VEGFB has similar affinity for VEGFR1 as VEGFA and
excess VEGFB can displace VEGFA from its ligand interactions with VEGFR1, thus
freeing endogenous VEGFA molecules to bind to VEGFR29. Thus, by
outcompeting VEGFA for ligand interactions with VEGFR1, VEGFB can be
considered an angiogenic factor, in spite of the weak signaling from
VEGB/VEGFR1 ligand interaction10. Metaphorically speaking, VEGFB can
“spring” VEGFA from the “trap” of VEGFR1, increasing the VEGFA concentration
available to bind to VEGFR2. As we will see, this pathway holds translational
relevance in activating adipose tissue angiogenesis.
VEGF’s and Obesity
Obesity is one of the major public health epidemics of our time, with more
than one in three American adults considered to be obese11. Oftentimes, obesity
is associated with a poor vascularization of adipose tissues and recent
translational research indicates that improved angiogenesis can help combat the
metabolic complications presented in obesity. VEGFA deficient mice have shown
exaggeration of obesity-related complications such as adipose tissue hypoxia and
inflammation on a High Fat Diet (HFD); overexpression of VEGFA in the same

Robciuc, MR et al. (2016). “VEGFB/VEGFR1-Induced Expansionof Adipose Vasculature
Counteracts Obesity and Related Metabolic Complications.” Cell Biology.
10 Koch, Sina and Claesson-Welsh, Lena.
11Weight-control Information Network.(2012) “Overweight and Obesity Statistics.” NIH and U.S.
Department of Health and Human Services
9
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study found improved adipose tissue functioning and reduced hypoxia12.
Unfortunately, direct VEGFA administration can be accompanied by dangerous
side effects, such endothelial cell permeability and microvascular disruptions13.
Thus, it would seem that direct VEGFA targeting could be too “potent,” and as
such alternatives to VEGFA must be found if angiogenesis-targeted therapies are
to possess translational viability.
In a paper published in April 2016, Robciuc et al. undertook the first
known studies targeting VEGFB interactions in adipose tissue14. Their
investigation revealed promising findings: VEGFB upregulation via VEGFB186
AAV (AAVB-186) increased white adipose tissue vascularization in white adipose
tissues, which they found reversed metabolic complications from obesity in HFD
mice. Crucially, VEGFB was shown to greatly increase insulin sensitivity and
functioning in HFD mice. The most striking finding of the paper was how partial
VEGFR1 endothelial cell deletion in Cre-lox recombinant mice (Flt-1 ECKO)
retained metabolic health and a lean physique even under a HFD. These mice
exhibited an increased adipose tissue capillary density and improved tolerance
of glucose and insulin, factors crucial in diabetes prevention. This result is
expected as per the mechanism described earlier, reducing the concentration of
“trap” VEGFR1 thus allowing more VEGFA/VEGFR2 angiogenesis. AAV-B186
further optimized the capillary density and tissue perfusion results in Flt-1 ECKO
mice, building the case for dual VEGFB/VEGFR1 targeting. The unprecedented
metabolic health and resistance to HFD in Flt-ECKO/AAVB-186 mice prompted

Sung, Hoon-Ki et al. (2013) “Adipose Vascular Endothelial Growth Factor Regulates Metabolic
Homeostasis through Angiogenesis.” Cell Biology.
13 Robciuc, MR et al. (2016). “VEGFB/VEGFR1-Induced Expansionof Adipose Vasculature
Counteracts Obesity and Related Metabolic Complications.” Cell Biology.
14 Robciuc, MR et al. Ibid
12

5

further investigation, revealing an increase in thermogenic genes from qPRC
data (PRDM16, UCP-1, Cidea) as well as increased respiration and energy usage
without harmful side effects. Since then, Robciuc et al. has been interested in
studying how this metabolic re-programming occurs via VEGFB. Thus, in
optimizing tissue vascularization and promoting thermogenic pathways in
adipose tissue, VEGFB/VEGFR1 targeting holds therapeutic potential as a
treatment strategy to reverse obesity and its metabolic complications.
CreLox System
Before I continue into the results section, I would like to briefly define the
CreLox system and its implications in the field of translational vascular medicine.
The CreLox construct is a recombinant technology which allows for precise and
controlled gene silencing. 34-bp, unidirectional loxP sites are inserted via cloning
vector immediately upstream and downstream of a targeted or “floxed” gene. Cre
recombinase recognizes the loxP sequences and catalyzes homologous
recombination between the two sites; if the loxP sites hold the same orientation
this will result in an excision of the targeted gene, thus preventing further
transcription or replication15. Expression is further nuanced by inserting the Cre
gene in tissue-specific promoters, ensuring the silencing activity occurs only a
particular tissue. Temporal control of this system is possible using the Cre-ERT
fusion protein, which incorporates a mutated form of the estrogen receptor into
the Cre recombinase protein. Under normal circumstances, this protein is
localized to the cytoplasm and binds to Hsp-90. In the presence of tamoxifen (4hydroxytamoxifen), Cre-ERT dissociates from Hsp-90, uncovering a nuclear
Zhang et al. (2012)“Conditional Gene Manipulation: Cre-Ating a New Biological Era.” Journal of
Zhejiang University Science. 13(7): 511-524
15
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localization signal in the ER component which relocates the protein to the
nucleus, where Cre recombinase can then catalyze gene silencing at loxP sites. In
mice, this technology allows silencing of a target gene during adulthood using a
tamoxifen gavage. Robciuc et al. used tamoxifen-induced used the Cre-Lox
system to generate VEGFR-1 ECKO mice, which under VEGFB AAV-transduction
exhibited a stark resistance to HFD and obesity-related complications. VEGFR1
deletion leads to embryonic lethality due to disorganized and overgrown
vasculature; Cre-ERT technology circumvented this issue allowing investigation
into VEGFR1 pathway manipulation. As such, this technology provides a useful
tool to study gene deletions in in vivo systems which might otherwise be
embryonically lethal.

Objectives
Working in Dr. Kari Alitalo’s group at the University of Helsinki with Dr.
M.R Robcuic, my first objective was to observe the interplay between VEGFA and
VEGFB in HUVEC in vitro models. Finding evidence of a robust but attenuated
angiogenic response to VEGFB in the HUVEC cultures would provide mechanistic
credence to future studies in vivo. Thus, our objective in these experiments was
to pinpoint the VEGFR1/VEGFB boosting of VEGFA/VEGFR2 angiogenesis in
HUVEC models.
I then moved to in vivo work, where I worked with Dr. Robciuc to
investigate how human VEGFBex1-5, an isoform of VEGFB which does not bind
to NRP-1, could induce angiogenesis in adipose tissue. This special selectivity for
VEGFR1 by VEGF-Bex1-5 can allow more exact targeting of the VEGFR1 pathway
without concern of NRP-1 binding. Based on the previously proposed
mechanism, we hypothesize that administration of VEGFB ex1-5 through AAV
7

injection will lead to a robust angiogenic response, increasing the vascular
content of white adipose tissue.
My final work with Dr. Robciuc was an exploratory project to characterize
the effects of a tissue-wide deletion of VEGFR1. We believe that using the ROSA
site, a promoter found in all mice cell types, a Cre-Lox construct can delete
VEGFR1 in all tissues with endothelial cells. Robciuc planned for future studies to
characterize how such a tissue-wide deletion might affect mammalian
vasculature and physiology as a whole. We also decided to analyze CD31, a
mammalian endothelial cell marker, and how it would be effected by VEGFR1
deletion and AAVB-186 transduction in both adipose tissue and serum.

Results
In Vitro HUVEC model
To investigate how VEGFB and VEGFA work together in endothelial cells,
we used P6 HUVEC (Human Umbilical Vein Endothelial Cells) cultures in a
signaling/starvation assay in which cultured cells are placed in minimal basal
media to prevent further proliferative signaling. After 48 hours in this condition,
the cells are then exposed to growth factors for 10 minutes, after which the cells
are lyzed and their contents extracted. Protein analysis by Western blot can
indicate the activity of signaling molecules. We examined ERK/pERK
(extracellular signaling related kinase, aka MAPK), a signaling protein in the
downstream cascade of VEGFR2. Phosphorylated ERK will affect secondary
messengers further down the VEGFR2 pathway to activate proliferative cellular
programs; thus a high ratio of pERK/ERK in the context of endothelial cells is
indicative of angiogenic signals. Hsc-70 concentrations were also measured to
serve as a housekeeping protein for data normalization.
8

While initial investigation into the mechanism of VEGFB in HUVEC models
revealed promising findings, the results were difficult to replicate. LICOR
imaging software was used to generate quantitative data from Western blot
images; pERK/ERK phosphorylation ratios were determined by comparing
relative signal density from the bands. pERK/ERK ratios for the dual
VEGFA/VEGFB cultures reside between the low concentration and high
concentration VEGFA standards, indicating a nuanced angiogenic response
(Fig.1). VEGFR2 phosphorylation also showed better ratios in the VEGFA/VEGFB
cultures, further providing support for VEGFB/VEGFR1 targeted
angiogenesis(Fig.2). However, these results proved difficult to isolate and
reproduce; incorporation of a VEGFB large-dose standard exhibited high levels of
pERK/ERK phosphorylation (results not shown), indicating the need for more
trials would be necessary to make definitive conclusions on VEGFA/VEGFB dual
interaction in vitro. Still, the findings presented in Fig.1 provide an example of
the VEGFA/VEGFB interaction that begs further investigation.
AAV-transduced mVEGFB ex1-5 can increase vascularity in white adipose
tissue
Next, we assessed the angiogenic capabilities of a mouse VEGFBex1-5
AAV in ApoE mice models. Due to the fatty composition of adipose tissues,
paraffin processing and embedding was selected as the sectioning method over
OCT cryosectioning. For blood vessel visualization, a streptavidin/biotinconjugated lectin procedure was used. Sections were first stained with
biotinylated lectin, which would detect proteoglycan molecules indicative of
endothelial cell extracellular matrices. Fluorescent streptavidin secondary
antigens would then interact with the biotin groups of the primary lectin
9

antigens, allowing visualization under fluorescent microscopy. Our results show
a consistent and robust angiogenic response from mVEGFB AAV treatment
(Fig.4). Image quantification using ImageJ software confirmed these findings.
Western Blot analysis with a mVEGFBex1-5 antibody indicates target antigen
expression in transduced samples, providing validation to our findings.

VEGFR1 Deletion via ROSA-promoter CreER fl/fl mice
The 2016 Robciuc et al. paper established a case for how dual AAVB186/Flt-1ECKO strategies can aid angiogenesis and improve metabolic health in
adipose tissue. Still, more characterization of the Flt-1 ECKO may be necessary to
advance its potential as a safe therapeutic strategy. Thus, my work has also
included an exploratory study investigating this strategy not only in adipose
tissue but across the many cells at once. To do this, the Cre-Lox deletion of Flt-1
was placed under the control of the ubiquitous ROSA promoter. Select samples of
which were provided Vegfb gene transduction via AAVB-186. To account for
dimorphic responses to these treatments, the results were divided between
males and females. We performed qPCR and ELISA for Flt-1 to measure the
effectiveness of the cross-tissue deletion in the subcutaneous fat and serum,
respectively. VEGFB transduction was also measured via qPCR and ELISA.
Our results found that the CreLox system holds potential to generate the
Flt-1KO across tissues. qPCR data from subcutaneous adipose tissue indicates
decrease in Flt-1 expression in both males and females, (Fig.5A,B). ELISA results
from serum also showed a decrease in VEGFR1 detection, indicating a successful
deletion across cell types (Fig.5C,D). VEGFB and CD31, an endothelial cell
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marker, were also measured for however the results from these were
unexpectedly variable and are not reported.

Discussion & Conclusion
Experiments targeting the VEGFB signaling in HUVEC cells were meant to
highlight the VEGFB/VEGFR1 interaction with VEGFA/VEGFR2 in an isolated,
controlled environment. Ideally, this in vitro data can explain the way these
growth factors act in mice models. To this end, the signaling experiments had
some early success, as seen with Fig.1 and to some degree Fig.2. This figure
shows that VEGFB administration, working with what are essentially
endogenous concentrations of VEGFA, will activate the proliferative ERK
pathway, but not to the dangerous degree as direct VEGFA administration.
Unfortunately, further experiments showed this result was difficult to isolate
from the direct effects of direct VEGFB stimulation, as shown in Fig.4. This
experiment was also hampered by ineffective positive controls of VEGFA. One
issue with these experiments is the passage number; usage of P8 cells can result
in inconsistent results. To truly examine a pathway under a controlled situation,
lower passage numbers would be necessary. Despite the difficulty in replicating
the results, these in vitro studies are still important avenues of continued
investigation. Through in vitro work, the precise mechanisms of the
VEGFB/VEGFR1 pathway can be observed without the biological complexity of
an in vivo system.
The experiments using hVEGFB ex1-5 in the ApoEKO mice are a promising
finding with respect to AAV-mediated VEGFB targeting to induce angiogenesis.
Lectin staining shows that the VEGFB transduction is efficient in increasing
capillary density, a sign of angiogenesis. That this can occur in ApoEKO mice, a
11

model of heart disease and cholesterol problems endemic of the modern
Western diet provides hope that angiogenic stimulation via VEGFB can be a
viable treatment. The result is also promising in a phylogenic sense- the fact that
a VEGFB vector can achieve its intended purpose in a mouse model makes a
promising case for use in human trials, given the relative reliability of the murine
disease model system. The effectiveness of the VEGFBex1-5 isoform is
encouraging as well, assuring that VEGFR1 targeting is sufficient to induce
adipose tissue angiogenesis (and that NRP-1 activation is not necessary). Thus,
these results show AAV-mediated VEGFBex1-5 transduction could hold a
possible therapeutic application in the future.
The ROSACre Flt-1KO model shows potential for further mechanistic
studies involving the deletion of Flt-1 in a variety of cell lines. The downregulation in subcutaneous tissue qPCR and lowered detection in serum ELISA of
VEGFR1 (Flt-1) indicate an effective knockout of the receptor not only in adipose
tissue cells but in other cells as well. Previous studies have mostly focused on the
local effects of VEGFR1 deletion in adipose endothelial cells; however the
deletion of this receptor across cell types may give further insight into its role in
the cell. For example, might VEGFR1deletion in cell types other than endothelial
cells also indirectly boost angiogenesis by reducing the concentration of “trap”
receptors? If this ROSACre could be optimized to work consistently, histological
analysis could provide more valuable information about how ROSA-site deletion
of VEGFR1 can affect the vasculature.
The hallmark of translational medical research is the exporting of
theoretical treatment strategies, characterized in vitro or in vivo, to a treatment
strategy relevant to human physiology and thus clinical trial. As an exploration
12

study based on the findings of Robciuc et al.’s 2016 paper, the work I have
presented in this thesis represents aspects of VEGFB/VEGFR1 targeting that are
necessary to address before manipulation of this pathway can become a viable
therapeutic option.
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Figure 1: HUVEC signaling assay comparing VEGFA and VEGFB administration
in terms of Western Blot signal intensity measured by LICOR imaging
software.(A) shows the phosphorylation ratio of pERK to ERK, indicating a
nuanced growth in the VEGFA/VEGFB samples. (B) provides the images of the
Western Blots used in the assay.

Figure 2: Measurement of VEGFR2/pVEGFR2 phosphorylation ratio in HUVEC
signaling assay.(A) shows attenuated response at the 1:50 VEGFA/VEGFB
condition but an unexpected drop in receptor activation at the 1:250 condition.
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Figure 3: VEGFB ex1-5 AAV-transduction of ApoEKO mice can strengthen
angiogenesis in adipose tissue. (A) Image J quantification of percent Lectin area
from microscopy photos, indicative of capillaries and thus angiogenic growth.
(B) Validation of results in the context of VEGFB transduction with VEGFB bands.
(C) Characteristic images from slides comparing Lectin stainings of capillaries (in
green).

Figure 4: ROSACre-ubiquitous deletion of Flt-1. (A) and (C) show qPCR fold
change for Flt-1 expression in males and females, respectively. Likewise, (B) and
(D) are ELISA detection of Flt-1 from serum samples. Negative fold change and
decreased serum concentration of Flt-1 indicate ROSACre-Lox deletion of Flt-1
can create a successful Flt-1KO model.
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Materials and Methods
Cells –Cells were cultured using supplemented endothelial cell growth media
from PromoCell (C-22210). Assays occurred consistently at P8.
Cell Lysis-Cellular or tissue samples are lyzed in 5%sucrose, .5% TRITON-X,
.5%NP-40 lysis buffer. Additional phosphotase (1:10) and Roche proteinase
inhibitors (1:25) are added to lysis buffer in cell work. On ice, adhesive cell
samples are washed twice with PBS, then administered 150 microliters of lysis
solution. Wells are then scratched with a pipette tip to detach adhesive cells, and
the lysates are collected.
Tissue samples are homogenized in lysis buffer with MoBio Power Lyzer 24 in
microcentrifuge tubes with 300 microliters of high-density zirconium oxide
beads at 3500 rpm x2 for 10 second intervals, with 10 seconds of rest between
each interval.
Western Blot- Lysed samples were examined for protein content using BCA assay
kits from ThermoFisher (23225) to equal protein concentration in loading.
Western blot ran with SDS Page solution using Bio-Rad Mini PROTEAN TGX Gels,
4-20% at 150 V for 75 mins. Transfer used Imobilion-FL PVDF membranes in a
transfer solution consisting of 700mL H20, 200mL MeOH, and 100 mL Transfer
mix (288g Glycine, 62g TRIS ad 2L). Transfer occurred at 400mA for 1 hr.
Ponceau staining used to visualize protein bands. LI-COR Odyssey blocking
solution diluted ½ in TBS used for blocking and antibody dilution. Membranes
blocked in solution for 1hr. Primary antibodies applied over night at +4C.
Fluroescent secondary antibodies applied for one hour; imaging with LICOR
Odyssey Fc imaging occurred up to 15 mins after.
Antibodies used in western blot:
ERK: Rb, Cell Signaling, 9102S, 1:1000
pERK: Rb, Cell Signaling, 9101L, 1:1000
hsc70: Ms, sc-7298, Santa Cruz Biotechnology, 1:10000
VEGFB: Ms, AF590, R&D, 1:500
Mice – Mice were obtained from Jackson Laboratories through the Provet system
under license of the University of Helsinki. Mice were raised to maturity under a
standard diet.
Tissue Collection- Mice were euthanized using Ketamine/xylasine anesthesia
mixture and cervical dislocation. Liver and inguinal white adipose tissue (eWAT)
were harvested and snap-frozen in liquid nitrogen.
qPCR- RNA separated from tissue samples using Mo Bio Power Lyzer 24 in
zirconium oxide bed microcentrifuge tubes containing 1 mL TRISure extraction
buffer (Bioline, BIO38032). 200 microliters chloroform added to lysates, which
are then centrifuged 12000 rcf at 4oC for 15 minutes. 350 microliters of aqueous
phase are mixed with 350 microliters of ethanol. RNA extracts then purified
using QIAGEN RNA purification kit. The purified RNA is then used to create cDNA
with the Bio-Rad cDNA iSCRIPT synthesis kit and a Bio-Rad Thermocycler. qPCR
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data was generated using VEGFB, HPRT, and 36B4 primers (Bio-RadSYBR) as
well as Flt-1 primers (Bio-Rad Taqman).
Flt-1 ELISA-96 well Maxisorp Nunc-Immuno Plate covered overnight with FLT-1
capture antibodies overnight. R&D DuoSet Flt-1 ELISA kit protocol was followed.
Serum samples diluted 1/5 in PBS +.1%BSA +.1% TWEEN.
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